Related Experiment Video

Updated: Aug 4, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment

Ron H J Mathijssen1, Ron H N van Schaik

  • 1Department of Medical Oncology and Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands. a.mathijssen@erasmusmc.nl

European Journal of Cancer (Oxford, England : 1990)
|December 6, 2005
PubMed

Insights

Genetic variations in drug-metabolizing enzymes, like Cytochrome P450, impact anticancer drug effectiveness and toxicity. Understanding these genetic factors and using phenotyping measures can reduce patient variability for better treatment outcomes.

Area of Science:

  • Pharmacogenomics
  • Oncology
  • Drug Metabolism

Background:

  • Anticancer agents often have a narrow therapeutic window, leading to toxicity or reduced efficacy if not dosed correctly.
  • Interpatient variability in drug response is a significant challenge in cancer treatment.
  • Genetic variations in drug-metabolizing enzymes are increasingly recognized as key contributors to this variability.

Purpose of the Study:

  • To investigate the role of genetic variations in drug-metabolizing enzymes on the pharmacokinetics and pharmacodynamics of anticancer agents.
  • To explore the potential of Cytochrome P450 genetic polymorphisms in explaining interpatient variability in anticancer drug response.
  • To assess the value of phenotyping measures in predicting drug metabolism and optimizing anticancer therapy.

Main Methods:

  • Review of literature on genetic polymorphisms in drug-metabolizing enzymes and their impact on anticancer drugs.
  • Analysis of studies correlating Cytochrome P450 genetic variations with anticancer drug metabolism.
  • Evaluation of phenotyping methods for predicting Cytochrome P450 expression and drug response.

Main Results:

  • Genetic variations in drug-metabolizing enzymes, particularly Cytochrome P450, significantly influence the metabolism of anticancer agents.
  • These genetic polymorphisms can explain a substantial portion of the variability observed in drug pharmacokinetics and patient response.
  • Phenotyping measures show promise in predicting enzyme activity and potentially reducing interpatient variability.

Conclusions:

  • Understanding the genetic basis of drug metabolism is crucial for personalized anticancer therapy.
  • Targeting genetic variations in Cytochrome P450 can help optimize dosing strategies for anticancer drugs.
  • Phenotyping offers a complementary approach to genetic testing for minimizing side effects and maximizing therapeutic efficacy in oncology.

More Related Videos

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...